Relmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as Futile

Dow Jones

Dec 04, 2024

By Denny Jacob

Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance.

The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants.

Relmada said no new safety signals were reported.

"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program," said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease.

Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 04, 2024 07:50 ET (12:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488198688"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488198688\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488198688?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488198688","market":"fut","top_or_hot":-1,"title":"Relmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as Futile","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance. \n</p>\n<p>\n  The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants. \n</p>\n<p>\n  Relmada said no new safety signals were reported. \n</p>\n<p>\n  \"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program,\" said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease. \n</p>\n<p>\n  Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2024 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as Futile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as Futile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-04 20:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance. \n</p>\n<p>\n  The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants. \n</p>\n<p>\n  Relmada said no new safety signals were reported. \n</p>\n<p>\n  \"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program,\" said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease. \n</p>\n<p>\n  Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 04, 2024 07:50 ET (12:50 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2488198688","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488198688","pubTimestamp":1733316600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance.The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants.Relmada said no new safety signals were reported.\"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program,\" said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease.Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","RLMD":"Relmada Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Relmada Therapeutics重度抑郁症治疗研究被评估为无效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9,"LENZ":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Relmada Therapeutics said an interim analysis of a study assessing a treatment for major depressive disorder is futile and unlikely to meet the primary efficacy endpoint with statistical significance. \n\n\n  The late-stage biotechnology company said an interim analysis of Reliance II conducted by the Independent Data Monitoring Committee determined its assessment of the Phase 3 study. Reliance II was designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder to be used in combination with other approved anti-depressants. \n\n\n  Relmada said no new safety signals were reported. \n\n\n  \"Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program,\" said Chief Executive Sergio Traversa. He added that Relmada will continue to advance a Phase 1 study of REL-P11 as a treatment of metabolic disease. \n\n\n  Trading was halted at 7:25 a.m. ET ahead of its disclosure and has yet to resume trading as of 7:47 a.m. ET. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2024 07:50 ET (12:50 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}